

Pesticide exposure and gender discrepancy in breast cancer

C. LEDDA¹, M. BRACCI², P. LOVREGGIO³, P. SENIA¹, M. LARROSA^{4,5},
B. MARTÍNEZ-JARRETA⁵, V. RAPISARDA¹

¹Occupational Medicine, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

²Occupational Medicine, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy

³Occupational Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy

⁴Internal Medicine Department, University Clinical Hospital Lozano Blesa, Zaragoza, Spain

⁵Forensic and Occupational Medicine, Faculty of Medicine, University of Zaragoza and Consolidated Research Group GIIIS-063-Aragón, Zaragoza, Spain

Abstract. – **OBJECTIVE:** It is biologically plausible that occupational and environmental pesticide exposure may contribute to breast cancer risk. Persistent chemical compounds, such as pesticides, tend to be lipophilic and are detected in human breast milk and adipose tissue. Therefore, the present systematic review aims to clarify the gender difference in breast cancer concerning pesticide exposure.

MATERIALS AND METHODS: A total of 70 studies satisfied the inclusion criteria and were included in the systematic review.

RESULTS: From the studies analyzed, it was observed that exposure to pesticides could be a risk factor for breast cancer in women, in particular in young women and in women who experienced menarche at a young age. In contrast, no association was found for breast cancer in men. Female breast cancer is correlated with estrogen receptor-negative tumor characteristics. Breast cancer in men was not correlated with pesticide exposure.

CONCLUSIONS: Breast cancer in women has been linked to estrogen receptor positivity, but this positivity appears to be inversely related to fertility. The estrogen-like effects of organochlorine pesticides could be the cause of the observed gender differences.

Key Words:

Breast neoplasm, Mammary cancer, Breast tumor, Endocrine disruptors, Environmental exposure, Occupational exposure.

divide in an uncontrolled manner, characteristically resulting in a lump or mass¹, consisting of four primary molecular subtypes and at least 21 different histological subtypes that differ in risk factors, staging, response to treatment, and outcomes¹.

Worldwide, there were approximately 2.1 million newly diagnosed female breast cancer (FBC) cases during 2018². In the same year, more than 600,000 women died from FBC².

Hereditary and genetic factors are the most frequent risk factors in FBC, including an individual or familial history of FBC and/or ovarian cancer and inherited mutations (i.e., BRCA1, BRCA2, and further breast cancer susceptibility genes). Other known risk factors for FBC are connected with menstruation (early age at menarche, age at menopause), reproduction (nulliparity, late age at first at childbirth, and fewer children), exogenous hormone intake (oral contraceptive use and hormone surrogate therapy), diet (alcohol intake), anthropometry (higher weight, weight gain during adulthood, and body fat distribution), shift work, and various occupational and environmental risk factors³⁻¹²; while breastfeeding and physical activity are recognized as protective factors³.

BC is a pathology that can also affect men¹³. Male breast cancer (MBC) is infrequent, representing 1% of cancers that happen in men and approximately 1% of all BC worldwide¹⁴⁻¹⁸. Fewer than 0.2% of cancer-related deaths in men can be attributed to MBC^{19,20}.

However, the incidence and prevalence of MBC fluctuate by race and ethnicity¹³. Indefi-

Introduction

Breast cancer (BC) is a group of diseases in which cells of the breast tissue change and

nite male populations, such as African Americans, have elevated rates of MBC in contrast with equivalent Caucasian, Hispanic, or Asian/Pacific Islander populations¹³. The median age at BC diagnosis is characteristically higher in men than in women, at 68 and 62, respectively¹³.

The first identification of MBC frequently occurs at a later stage than in FBC. MBC is often further advanced at the instance of identification and may include, for example, a superior cancer dimension, lymph node involvement, and remote metastases^{14,15,21-26}.

Genetic risk factors for MBC are similar, but not identical, to those in women. Family history is pertinent for both^{21,22}, and BRCA2 mutations and rearrangements play an important role in MBC²³⁻²⁶. Between 5-10% of men with BRCA2 mutations can develop BC²⁷⁻³¹. However, one investigation³² of 102 Italian MBC patients established no BRCA1 or BRCA2 reorganizations. Circumstances that modify the ratio of estrogen to androgen have been connected to MBC. Klinefelter's syndrome^{33,34}, exogenous estrogen or testosterone use³⁵, obesity^{34,36-38}, orchitis/epididymitis³⁴, finasteride^{39,40}, and prostate cancer treated with estrogens, have been linked with MBC⁴¹. Participating in sports appears to decrease risk³⁴. Some investigations have not established an association between smoking, alcohol intake, and MBC^{34,38}. Epidemiological studies have evaluated occupational exposure, as well as exposure to electromagnetic fields⁴²⁻⁴³, heat⁴⁴, and polycyclic aromatic hydrocarbons, pesticides, and other chemicals⁴⁵⁻⁴⁷ as possible risk factors for MBC. However, the data have been varied and questionable^{48,49}.

It is biologically plausible that occupational and environmental exposure may contribute to BC risk; in particular, persistent chemical compounds (i.e., pesticides) tend to be lipophilic and are detected in human breast milk and adipose tissue⁵⁰⁻⁵². As an endocrine disruptor, pesticide exposure may cause BC by altering hormonal activity or causing epigenetic damage⁵³. Therefore, the present systematic review aims to clarify the gender differences in BC with regard to pesticide exposure.

Materials and Methods

This systematic review was carried out in accordance with the PRISMA statement⁵⁴.

Literature Search

SCOPUS, Medline (using PubMed as the search engine), Embase, and Web of Science databases were examined to identify relevant research available until November 1, 2020, to investigate the association between pesticide exposure and BC, with BC as the principal outcome.

A MeSH term was used with the following entry terms: "Breast Neoplasms" AND "Pesticides"; "Breast Neoplasms" AND "Agrochemicals"; "Breast Neoplasms" AND "Pesticide Residues".

A search for research manuscripts that were appropriate for inclusion in this systematic review was conducted, and the papers of significance therein were collected and reviewed.

Inclusion and Exclusion Criteria

The subsequent inclusion criteria were assumed: (1) studies that assessed BC in relation to pesticide exposure assessments. The following exclusion criteria were applied: (1) animal studies, (2) scientific articles that are not published in the English language; and (3) reviews, conference abstracts or letters to the editor.

For matching studies, only articles with supplementary detailed information were included.

Quality Assessment and Data Extraction

Two reviewers (CL and VR) recovered articles independently. The title, abstract, and full text of each potentially relevant study was reviewed. Any divergence on the eligibility of the papers was determined through debate or by consulting an additional reviewer (MB). The following information was extracted from all papers: authors, year of publication, exposure, study design, period, population observed, age population observed, country, and conclusion of the study.

Results

Characteristics of Eligible Studies

After a search of the scientific literature by the reviewers, 312 research papers were collected, and five were replicated. A total of 307 were investigated following a review of the title and abstract, and 237 studies were deemed ineligible after reviewing the manuscript. In summary, 70 studies satisfied the inclusion criteria and were included in the systematic review⁵⁵⁻¹²¹. A flow-chart showing the choice of studies is presented in Figure 1.




Figure 1. Flow diagram illustrating included and excluded studies in this systematic review.

Researchers from various countries conducted the investigations: 35 in the USA; four each in Canada, Spain, and the UK; three each in Australia, Brazil, Canada, China, and Denmark; two each in Belgium, Germany, Japan, Italy, and Mexico; and one each in Colombia, Egypt, France, Greece, India, the Netherlands, Norway, Palestine, Sweden, Switzerland, and Taiwan (Figure 2).

The study designs were as follows: 43 case-control, 12 cohorts, eight mortality cohort, six incidence cohort, two ecological, and one observational study.

To highlight gender differences, it was decided to divide the studies between FBC (Table I) and MBC (Table II).

Female Breast Cancer

The studies included 63 articles that aimed to establish an association between FBC and pesticide exposure. The studies were performed over a long period: 1960-2019. In recent years, the pesticides used have varied considerably; some have not been available for a long time, while others have been introduced to the market more recently. Furthermore, pesticides are persistent pollutants in the environment, and current exposure may be affected by remote exposure because of residual contamination in some areas of the globe⁵⁰.

A total of 13 (21%) studies investigated work-related exposure in women^{55,58,64,65,67,69,75-78,88,107,112}, 46 (73%) investigated environmental exposure^{56,57,59-63,66,68,71-74,79,81,83-87,89-104,106,108-111,113-118}, and four (6%) investigated both exposure factors^{70,80,82,105}.

A total of 25 studies analyzed pesticide metabolites in serum and BC incidence^{56,57,60-63,66,68,72-74,81,92,96,98,104,108,110,111,116-118}, and five measured the concentrations of pesticides (metabolites) in BC tissue^{70,87,89,91,113}.

By analyzing the results of the studies, some opposing results emerged. In particular, 39 (62%) investigations underline an association between exposure to pesticides and FBC^{55,56,59,69-71,74-83,86,87,89,91,93-95,97-99,101,103,106-118}; whereas the other 24 (38%) highlight the opposite^{56-59,60-68,72,73,84,85,88,90,92,96,100,102,104,105}.

The association between FBC and pesticide exposure was asserted by 10 occupational and 29




Figure 2. Graphical map of the geographical distribution of the selected studies.

Table I. Main characteristics of eligible studies of FBC.

Reference	Exposure	Study design	Period	Population observed	Age (years)	Country	Conclusions
Davis et al ⁵⁵	Occupational	Mortality cohort study	1968-1986	163	n.d.	USA, Japan, UK, France, Italy, and West Germany	Probable association
Wolff et al ⁵⁶	Environmental	Case-control study	1985-1991	58	n.d.	USA	BC was strongly associated with high DDE serum concentration
Krieger et al ⁵⁷	Environmental	Case-control study	1960-1990	150	n.d.	USA	BC was not associated with DDE serum concentration
Wiklund and Dich ⁵⁸	Occupational	Incidence cohort study	1971-1987	4747	n.d.	Sweden	No association with exposure to pesticides
Kettles et al ⁵⁹	Environmental	Incidence cohort study	1991-1994	n.d.	n.d.	USA	Relationship between exposure to triazine and FBC
Van 'T Veer et al ⁶⁰	Environmental	Case-control study	1991-1992	265	50-74	Germany, Netherlands, Northern Ireland, Switzerland, Spain	BC was not associated with DDE serum concentration in postmenopausal women
López-Carrillo et al ⁶¹	Environmental	Case-control study	1994-1996	141	20-79	Mexico	BC was not associated with DDE serum concentration
Hunter et al ⁶²	Environmental	Case-control study	1989-1992	236	59 (43-69)	USA	BC was not associated with DDE serum concentration
Olaya-Contreras et al ⁶³	Environmental	Case-control study	1995-1996	153	26-75	Colombia	BC was associated with DDE serum concentration
Petralia et al ⁶⁴	Occupational	Incidence cohort study	1980-1984	69	n.d.	China	Exposure to pesticides was not related to the risk of FBC
Fleming et al ⁶⁵	Occupational	Mortality cohort study	1975-1993	4	n.d.	USA	No association with exposure to pesticides
Mendonça et al ⁶⁶	Environmental	Case-control study	1995-1996	177	57 (30-75)	Brazil	BC was not associated with DDE serum concentration
Fleming et al ⁶⁷	Occupational	Incidence cohort study	1975-1993	26	n.d.	USA	No association with exposure to pesticides
Ward et al ⁶⁸	Environmental	Case-control study	1975-1993	300	41.1±6.8	Norway	BC was not associated with DDE serum concentration
Band et al ⁶⁹	Occupational	Case-control study	1980-1995	2038	n.d.	Canada	Positive association with pesticide exposure
Aronson et al ⁷⁰	Environmental and occupational	Case-control study	1995-1997	430	57.7 ± 11.6 (cases) 53.9 ± 10.9 (controls)	Canada	Association with Mirex and DDE concentration in breast adipose tissue

Continued

Table 1 (Continued). Main characteristics of eligible studies of FBC.

Reference	Exposure	Study design	Period	Population observed	Age (years)	Country	Conclusions
Høyer et al ⁷¹	Environmental	Cohort study	1976-1992	717	54.6 (mean)	Denmark	Possible association between organochlorine exposure and BC risk
Stellman et al ⁷²	Environmental	Case-control study	1994-1996	1030	n.d.	USA	BC was not associated with DDE serum concentration
Millikan et al ⁷³	Environmental	Case-control study	1993-1996	1730	50.8 (23-74)	USA	BC was not associated with DDE serum concentration
Demers et al ⁷⁴	Environmental	Case-control study	1994-1997	534	53 ± 10	Canada	p,p'-DDE may increase BC aggressiveness
Duell et al ⁷⁵	Occupational	Case-control study	1993-1996	1652	20-74	USA	Positive association with pesticide exposure
Dolapsakis et al ⁷⁶	Occupational	Cohort study	1988-1993	1053	40-75	Greece	Exposed have a higher risk of breast lesions
Janssens et al ⁷⁷	Occupational	Mortality cohort study	1985-1994	589	n.a.	Belgium	Positive association with pesticide exposure
Thomas et al ⁷⁸	Occupational	Mortality cohort study	1980-1990	2548	15-65	USA	Positive association with pesticide exposure
Mathur et al ⁷⁹	Environmental	Case-control study	2002	185	21-70	India	Positive association with pesticide exposure
Safi ⁸⁰	Environmental and occupational	Observational study	1990-1999	796	0-65+	Palestine	Association with exposure to pesticides
Charlier et al ⁸¹	Environmental	Case-control study	1999-2000	409	54 ± 12	Belgium	BC was associated with serum pesticide metabolite concentration
Brody et al ⁸²	Environmental and occupational	Case-control study	1988-1995	2081	60-80	USA	Increased risk only for pesticide applicators
O'Leary et al ⁸³	Environmental	Case-control study	1980-1992	315	61.1 ± 11.4	USA	Association with BC only in long-term resident within 1 mile of hazard waste sites containing organochlorine pesticides
Muir et al ⁸⁴	Environmental	Ecological study	1989-1991	n.d.	> 45	UK	No association between pesticide exposure and BC
Reynolds et al ⁸⁵	Environmental	Cohort study	1995	133,479	40-59	USA	No association between pesticide exposure and BC
Mills et al ⁸⁶	Environmental	Case-control study	1988-2001	768	n.d.	USA	Chlordane, malathion, and 2,4-D were associated with increased risk for BC (stronger in young women)
Raaschou-Nielsen et al ⁸⁷	Environmental	Case-control study	1993-1997	818	57.4 ± 4.0	Denmark	Correlation between estrogen receptor-negative BC and high organochlorine concentrations in breast tissue
Engel et al ⁸⁸	Occupational	Cohort study	1993-1997	30454	18-96	USA	No association between pesticide exposure and BC
Zumbado et al ⁸⁹	Environmental	Cohort study	1997-1998	783	6-75	Spain	Possible association between estrogenic BC and p,p'-DDT concentration

Continued

Table I (Continued). Main characteristics of eligible studies of FBC.

Reference	Exposure	Study design	Period	Population observed	Age (years)	Country	Conclusions
Alavanja et al ⁹⁰	Environmental	Cohort study	1993-2002	52395	n.d.	USA	No association between pesticide exposure and BC
Waliszewski et al ⁹¹	Environmental	Case-control study	2004	254	49	Mexico	Correlation between BC and organochlorine concentrations in breast tissue.
Rubin et al ⁹²	Environmental	Case-control study	1981-1987	126	< 54	USA	BC was not associated with DDE serum concentration
Khanjani et al ⁹³	Environmental	Ecological study	1983-2002	797	n.d.	Australia	Limited association between BC and organochlorine pesticide exposure
Teitelbau et al ⁹⁴	Environmental	Case-control study	1993-1997	1508	n.d.	USA	Association between pesticide exposure and BC
Cohn et al ⁹⁵	Environmental	A prospective nested case-control study	1959-1967	258	n.d.	USA	Exposure to p,p'-DDT early in life may increase BC risk
Itoh et al ⁹⁶	Environmental	Case-control study	2001-2005	806	53.8 ± 0.5	Japan	No association with serum pesticide metabolite concentration
Jacome et al ⁹⁷	Environmental	Cohort study	2005-2008	110	20-35	Brazil	Association between pesticide exposure and BC
Xu et al ⁹⁸	Environmental	Cohort study	1999-2004	4172	20-75	USA	BC was associated with serum organochlorine pesticide metabolite concentration
Zota et al ⁹⁹	Environmental	Case-control study	1988-1995	1508	40-85	USA	Moderate association between pesticide exposure and BC
Farooq et al ¹⁰⁰	Environmental	Case-control study	1994-1996	1205	50-70	USA	No association between pesticide exposure and BC
Waggoner et al ¹⁰¹	Environmental	Mortality cohort study	1993-2007	89656	n.a.	USA	Association between pesticide exposure and BC
Ashley-Martin et al ¹⁰²	Environmental	Case-control study	1999-2002	828	54.8 ± 53.4-56.0	Canada	No association between pesticide exposure and BC
El-Zaemey et al ¹⁰³	Environmental	Case-control study	2009-2011	2912	30-75	Australia	Association between pesticide exposure and BC at a young age of exposure
Holmes et al ¹⁰⁴	Environmental	Case-control study	1999-2002	170	30-88	USA	No association with serum pesticide metabolite concentration
El-Zaemey et al ¹⁰⁵	Environmental and occupational	Case-control study	2009-2011	2912	30-75	Australia	No association between pesticide exposure and BC
Parrón et al ¹⁰⁶	Environmental	Case-control study	1998-2005	34191	n.d.	Spain	Association between pesticide exposure and BC
Lerro et al ¹⁰⁷	Occupational	Cohort study	1993-1997	30003	n.d.	USA	Association between pesticide exposure and BC
Cohn et al ¹⁰⁸	Environmental	A prospective nested case-control study	1959-1967	472	n.d.	USA	Association between in utero DDT exposure and risk of BC in young women and possible association with more aggressive BC
Salerno et al ¹⁰⁹	Environmental	Case-control study	2002-2009	12378	25-79	Italy	Association between pesticide exposure and BC

Continued

Table 1 (Continued). Main characteristics of eligible studies of FBC.

Reference	Exposure	Study design	Period	Population observed	Age (years)	Country	Conclusions
He et al ¹¹⁰	Environmental	Case-control study	2015-2016	102	52.4 ± 10.6	China	BC was associated with serum pesticide metabolite concentration
Wielsoe et al ¹¹¹	Environmental	Case-control study	2000-2003 2011-2014	161	52±9	Denmark	BC was associated with blood pesticide metabolite concentration
Engel et al ¹¹²	Occupational	Cohort study	1993-1997	52394	n.d.	USA	Several organophosphate insecticides were associated with elevated BC risk
Eldakroory et al ¹¹³	Environmental	Cohort study	2014-2015	70	n.d.	Egypt	BC was associated with organochlorine pesticides in tissue specimens
Chang et al ¹¹⁴	Environmental	Cohort study	1996-2013	3141	n.d.	Taiwan	BC was associated with DDT exposure in childhood
Silva et al ¹¹⁵	Environmental	Case-control study	2017-2018	351	54.3 ± 8.4 (cases) 51.1 ± 10.6 (controls)	Brazil	Women exposed to pesticides aged over 50 years and who experienced early menarche had higher BC risk
Huang et al ¹¹⁶	Environmental	Case-control study	2014-2016	374	52.00 ± 9.89 (cases) 48.64 ± 10.88 (controls)	China	Association with p,p'-DDT, and p,p'-DDE and BC risk
Cohn et al ¹¹⁷	Environmental	A prospective nested case-control study	1959-1967	585	n.d.	USA	p,p'-DDT is a risk factor for BC through age 54 years
Cohn et al ¹¹⁸	Environmental	A prospective nested case-control study	(1959-1967) 1998	266	<50 years	USA	Association with p,p'-DDT, and p,p'-DDE and BC risk

Table II. Main characteristics of eligible studies of MBC.

Reference	Exposure	Study design	Period	Population observed	Age (years)	Country	Conclusions
Cocco et al ¹¹⁹	Occupational	Case-control study	1985-1986	3	n.d.	USA	No association with exposure to pesticides
Fleming et al ¹²⁰	Occupational	Mortality cohort study	1975-1993	0	/	USA	No cases of MBC were observed
Fleming et al ¹²¹	Occupational	Incidence of cohort study	1975-1993	2	n.d.	USA	No association with exposure to pesticides
Safi ⁸⁰	Environmental and occupational	Observational study	1990-1999	5	2 (15-44 y) 2 (55-64 y) 1 (+65 y)	Palestine	No association with exposure to pesticides
Fleming et al ¹²²	Occupational	Mortality cohort study	1986-1994	0	/	USA	No cases of MBC were observed
Macfarlane et al ¹²³	Occupational	Incidence cohort study	1991-2002	6	n.d.	UK Gulf war veterans	No association with exposure to pesticides
Villeneuve et al ¹²⁴	Occupational	Cohort study	1995-1997	27	n.d.	Europe	No association with exposure to pesticides
Waggoner et al ¹⁰¹	Environmental and occupational	Mortality study	1993-1997	12	n.d.	USA	Negative association
Parrón et al ¹²⁵	Environmental	Case-control study	1998-2005	n.d.	n.d.	Spain	No significant association
Salerno et al ¹⁰⁹	Environmental and occupational	Case-control study	2002-2009	1	n.d.	Italy	Non-analyzable data

environmental studies. Beyond investigating the correlation between FBC and pesticide exposure, six focused on occupational exposure and 18 on environmental exposure.

By analyzing the subgroup of 30 reports that involved measuring pesticide metabolites in biological samples, it was observed that 19 (63%) indicated an association between pesticide metabolites and FBC, and 11 (37%) showed no association. In particular, the investigations affirming a strong association were the most recent, and therefore were performed using more reliable analytical methods such as gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Furthermore, studies that show a positive correlation between pesticide exposure and FBC highlight a strong association with the onset of carcinoma at a young age and with organochlorine pesticides.

Among the studies in which a statistically significant correlation was found between BC and pesticides, the latter were usually organochlorine pesticides.

Finally, it is possible to affirm that there can be a link between exposure to some classes of pesticides and the onset of FBC.

Male Breast Cancer

For this systematic review, 10 investigations were studied. Table II lists the main characteristics of eligible studies for MBC.

Cocco et al¹¹⁹ investigated the link between MBC risk and some occupational risk factors, including pesticides; they noticed a negative association between occupational exposure to herbicides and other pesticides.

Fleming et al¹²⁰⁻¹²² conducted three studies on health outcomes in pesticide applicators, two on mortality^{120,122}, and one on incidence¹²¹. No cases of MBC were reported in a mortality study¹²⁰⁻¹²². A total of two cases were observed in the incidence study¹²¹, but no correlation was found between pesticide exposure and MBC.

Safi⁸⁰ described the association between chronic exposure to pesticides and recorded cases of cancer in an area where pesticides were used extensively. An incidence of 0.1% was reported, but also, in this case, no association between exposure to pesticides and MBC was established.

An incidence cohort study among UK Gulf war veterans was carried out by Macfarlane et al¹²³, who observed six cases of MBC, but no association was reported with pesticide exposure.

Later, a specific study on MBC and occupational exposure to endocrine-disrupting chemicals, including pesticides, in eight European Countries was conducted by Villeneuve et al¹²⁴. Exposure to pesticides was not associated with MBC.

Of the three mortality cohort studies in licensed pesticide users in the USA, in the two conducted by Fleming et al¹²⁰⁻¹²², no cases of MBC were found, while in the study led by Wagoner et al¹⁰¹, 11 cases were found, but no association with previous exposure to pesticides was detected.

Environmental exposure to pesticides and cancer risk was evaluated by Parron et al¹²⁵ but no significant association was found for MBC.

Finally, a population-based case-control study investigated the association between farming (a proxy for pesticide exposure) and cancer in Italy¹⁰⁹, but they found only one case of MBC.

Therefore, in light of the results obtained, no study correlated pesticide exposure with MBC.

Discussion

Exposure to pesticides has become ubiquitous for workers and the general population because of their extensive use. The routes of pesticide exposure are different between occupational and environmental exposure, and it appears that the effects of exposure are also different for men and women.

Pesticides have been studied as a risk factor for many chronic-degenerative diseases¹²⁶⁻¹⁴⁰.

From the studies analyzed, we can affirm that exposure to pesticides could be a risk factor for FBC, in particular in young women and in women who had menarche at a young age. In contrast, no association was found for MBC.

Organochlorine pesticides, including 1,1'-(2,2,2-Trichloroethane-1,1-diyl)bis(4-chlorobenzene) (DDT), were used extensively in the USA from the early 1940s until the 1960s for insect control (i.e., residential use) and outdoor (i.e., agriculture). The use of DDT peaked in the USA in the early 1960s and was prohibited in 1972. Other organochlorines include pesticides used in lesser amounts, such as lindane and hexachlorobenzene.

Organochlorine pesticides degrade slowly but are lipid-soluble; therefore, they bioaccumulate in the food chain and may be observed in human adipose tissue, blood, and breast milk. The most

prevalent organochlorine residue usually found in human tissues is 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE), the major metabolite of DDT¹³².

DDE was found in the serum and breast adipose tissue of patients with FBC in various studies and often correlated with FBC^{56,57,60-63,66,68,72-75,81,92,96,98,104,108,110,111,116-118}. However, in a lower number of studies, this association was not observed^{70,87,89,91,113}.

The studies that do not support correlation are older papers and were therefore conducted with less precise analytical methods.

Recently, many research groups' interest has been focused on the potential of various chemicals to act as "endocrine disruptors." An endocrine disruptor is a compound that interferes with the endocrine system's role by mimicking a hormone, interrupting the effects of a hormone, or by stimulating or inhibiting the release or transport of hormones¹⁴³. Several organochlorine pesticide metabolites, including DDE, are screened as endocrine disruptors because they showed slightly estrogenic or antiestrogenic activity in experimental investigations¹⁴⁴⁻¹⁴⁵. Furthermore, carcinogenic behaviors have been highlighted in animal models¹⁴⁶⁻¹⁴⁷.

In 1993, a case-control study carried out by Wolff et al⁵⁶ in New York found the highest serum levels of DDE in FBC compared with a paired woman without BC. Since 1993, other research groups have attempted to confirm the associations observed in the Wolff et al study⁵⁶, but these did not find the same association^{57,60-62,66,68,72,73,92,96}.

In a pooled analysis of other investigations^{63,70,74,86,87}, the relative risks for FBC were significantly associated with women in the highest quintiles for DDE concentration.

Recent researches^{89,91,98,108-118} have highlighted the possibility that exposure to organochlorine pesticides may underly higher rates of FBC.

Exposure to organochlorine pesticides appears to amplify the risk of FBC. A study carried out by Raaschou-Nielsen et al⁸⁷ on FBC grouped by tumor characteristics such as estrogen receptor and progesterone receptor status, correlated high DDE concentrations with estrogen receptor-negative FBC.

The etiology of estrogen receptor-negative FBC is unknown but is associated with a young age of onset and early menarche^{148,149}.

Generally, MBC was highly estrogen receptor positive compared with FBC. FBC has also been linked to estrogen receptor positivity, but

this positivity appears to be inversely related to female fertility. Typically, it is known that older women are more likely to be estrogen receptor-positive¹⁵⁰.

The associations observed by Raaschou-Nielsen et al⁸⁷ seem contrary to the extensively established mechanism through which estrogens may cause BC by binding with estrogen receptors¹⁵¹. The mechanism, therefore, remains unclear. Some organochlorine pesticides and several of their metabolites have been found to stimulate estrogen-like effects in exposed humans. Consequently, they could be involved in endocrine pathologies connected with estrogenic effects, such as BC¹⁵²⁻¹⁵⁴.

Cohn et al⁹⁵ and other research groups¹⁵⁵⁻¹⁵⁸ have provided more experimental evidence on the timing of environmental exposure to pesticides during susceptible periods, also called "windows," including in utero, and in childhood, puberty, and pregnancy, which can cause a change in the regulation of breast development that can provoke BC in adulthood. It is impossible to estimate the role of genetic susceptibility; however, from this review's results, pesticide exposure and BC could be associated with in utero exposure and early BC. It is probable that pesticides may either provoke a non-germline genetic susceptibility or otherwise interact with an unknown genetic susceptibility. The recognized association between BC and protracted exposure to estrogens suggests that environmental estrogens, such as organochlorine pesticides, could play a critical role in the cellular and molecular changes that happen throughout breast carcinogenesis. These alterations change healthy cells to latent tumor cells by shifting the genetic material that facilitates their proliferation¹⁵⁹⁻¹⁶⁴. Furthermore, there is evidence¹⁵¹ to support estrogen receptor-independent mechanisms in estrogen-mediated BC development through the production of genotoxic estrogen metabolites, which can provoke DNA damage and/or form DNA adducts¹⁵¹.

This finding provides the biological foundation to support the findings of the studies that link exposure to chlorinated pesticides to BC in the present systematic review.

The current review provides a foundation for the link between exposure to chlorinated pesticides and FBC.

The present study's limitations include a loss of information about the exposure that occurred many years before the onset of BC; epidemiolog-

ical studies are conducted in different countries, which use different products and cultivation systems. Furthermore, certain studies do not report details on pesticide exposure or their concentration in biological fluids and/or tissues.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Funding

The authors declare that there is no funding available for the publication of this paper.

References

- 1) <https://www.who.int/cancer/detection/breastcancer/en/> (Accessed on 30/01/2020)
- 2) Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68: 394-424.
- 3) Brinton LA, Gaudet MM, Gierach GL. Breast cancer. In: Schottenfeld and Fraumeni Cancer epidemiology and prevention, fourth edition, Oxford Scholarship, 2017; pp. 861-888.
- 4) Bracci M, Ciarapica V, Zabaleta ME, Tartaglione MF, Pirozzi S, Giuliani L, Piva F, Valentino M, Ledda C, Rapisarda V, Stevens RG, Santarelli L. BRCA1 and BRCA2 gene expression: diurnal variability and influence of shift work. *Cancers* 2019; 11: 1146.
- 5) Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. *Breast Cancer Res* 2004; 6: 229-239.
- 6) Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. *JAMA* 2002; 288: 321-333.
- 7) Leonardi GC, Rapisarda V, Marconi A, Scalisi A, Catalano F, Proietti L, Travali S, Libra M, Fenga C. Correlation of the risk of breast cancer and disruption of the circadian rhythm (review). *Oncol Rep* 2012; 28: 418-428.
- 8) Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K. Population-attributable risk proportion of clinical risk factors for breast cancer. *JAMA Oncol* 2017; 3: 1228-1236.
- 9) Hjerkind KV, Ellingjord-Dale M, Johansson ALV, Aase HS, Hoff SR, Hofvind S, Fagerheim S, Dos-Santos-Silva I, Ursin G. Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program. *Cancer Epidemiol Biomarkers Prev* 2018; 27: 1065-1074.
- 10) Holm J, Eriksson L, Ploner A, Eriksson M, Rantalainen M, Li J, Hall P, Czene K. Assessment of breast cancer risk factors reveals subtype heterogeneity. *Cancer Res* 2017; 77: 3708-3717.
- 11) Zhang L, Huang Y, Feng Z, Wang X, Li H, Song F, Liu L, Li J, Zheng H, Wang P, Song F, Chen K. Comparison of breast cancer risk factors among molecular subtypes: a case-only study. *Cancer Med* 2019; 8: 1882-1892.
- 12) Chopra-Tandon N, Wu H, Arcaro KF, Sturgeon SR. Relationships between global DNA methylation in circulating white blood cells and breast cancer risk factors. *J Cancer Epidemiol* 2017; 2017: 2705860.
- 13) Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. *Breast Cancer Res Treat* 2019; 173: 37-48.
- 14) Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JMS, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. *J Clin Oncol* 2010; 28: 2114-2122.
- 15) Cutuli B. Strategies in treating male breast cancer. *Expert Opin Pharmacother* 2007; 8: 193-202.
- 16) Gennari R, Curigliano G, Jereczek-Fossa BA, Zurrida S, Renne G, Intra M, Galimberti V, Luini A, Orecchia R, Viale G, Goldhirsch A, Veronesi U. Male breast cancer: a special therapeutic problem. Anything new? (review). *Int J Oncol* 2004; 24: 663-670.
- 17) Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. *Lancet* 2006; 367 595-604.
- 18) Yoney A, Kucuk A, Unsal M. Male breast cancer: a retrospective analysis. *Cancer Radiother* 2009; 13: 103-107.
- 19) Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 20-26.
- 20) Burga AM, Fadare O, Lininger RA, Tavassoli FA. Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. *Virchows Arch* 2006; 449: 507-512.
- 21) Darkeh MHSE, Azevedo E. Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches. *Int J Clin Med* 2014; 5: 1068-1086.
- 22) Giotta F, Acito L, Candeloro G, Del Medico P, Gadaleta-Caldarola G, Giordano G, Gueli R, Lugini A, Magri V, Mandarà M, Masci G, Pisconti S,

- Pistelli M, Rizzi A, Salesi N, Schirone A, Scognamiglio G, Tedeschi M, Zucchinelli P. Eribulin in male patients with breast cancer: the first report of clinical outcomes. *Oncologist* 2016; 21: 1298-1305.
- 23) Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. *Cancer* 1998; 83: 498-509.
 - 24) Joshi MG, Lee AKC, Loda M, Camus MG, Pedersen C, Heatley GJ, Hughes KS. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. *Cancer* 1996; 77: 490-498.
 - 25) Arslan UY, Öksüzöğlü B, Özdemir N, Aksoy S, Alkiş N, Gök A, Kaplan MA, Gümüş M, Berk V, Uncu D, Baykara M, Çolak D, Üyetürk U, Türker I, Işıkdoğan A. Outcome of non-metastatic male breast cancer: 118 patients. *Med Oncol* 2012; 29: 554-560.
 - 26) Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. *J Clin Oncol* 2010; 28: 232-239.
 - 27) Rudlowski C. Male breast cancer. *Breast Care* 2008; 3: 183-189.
 - 28) Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L. Male breast cancer: genetics, epigenetics, and ethical aspects. *Ann Oncol* 2013; 24 Suppl 8: viii75-viii82.
 - 29) Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. *Am J Hum Genet* 1998; 62: 676-689.
 - 30) Greene MH. Genetics of breast cancer. *Mayo Clin Proc* 1997; 72: 54-65.
 - 31) Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon S-, Caligo MA, Spugnese L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuehauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim S-, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A, Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KBM, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes A, Ejlersen B, Hansen TVO, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the consortium of investigators of modifiers of BRCA1/2. *Breast Cancer Res* 2016; 18: 15.
 - 32) Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. *Breast Cancer Res Treat* 2008; 110: 161-167.
 - 33) Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. *Bio Med Res Int* 2013; 2013: 928562.
 - 34) Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, LaDuca H. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. *Breast Cancer Res Treat* 2017; 161: 575-586.
 - 35) Liang M, Zhang Y, Sun C, Rizeq FK, Min M, Shi T, Sun Y. Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysis. *Mol Diagn Ther* 2018; 22: 397-407.
 - 36) Severson TM, Zwart W. A review of estrogen receptor/androgen receptor genomics in male breast cancer. *Endocr Relat Cancer* 2017; 24: R27-R34.
 - 37) Wu Q, Li J, Zhu S, Wu J, Li X, Liu Q, Wei W, Sun S. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype. *Oncotarget* 2016; 7: 87532-87542.
 - 38) El-Tamer MB, Komenaka IK, Troxel A, Li H, Joseph K, Ditkoff B, Schnabel FR, Kinne DW. Men with breast cancer have better disease-specific survival than women. *Arch Surg* 2004; 139: 1079-1082.
 - 39) Marchal F, Salou M, Marchal C, Lesur A, Desandes E. Men with breast cancer have same disease-specific and event-free survival as women. *Ann Surg Oncol* 2009; 16: 972-978.
 - 40) Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of

- the breast. *Am J Clin Oncol Cancer Clin Trials* 1987; 10: 55-60.
- 41) Scott-Conner CEH, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. *Surgery* 1999; 126: 775-781.
 - 42) Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, Jahn M, Costa SD. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. *Breast Cancer Res Treat* 2013; 137: 465-470.
 - 43) Reinisch M, Seiler S, Hauzenberger T, Schmatloch S, Strittmatter HJ, Zahm DM. Male-GBG54: a prospective, randomised, multi-centre, phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. Presented at the 2017 San Antonio Breast Cancer Symposium, 2017.
 - 44) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Genari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorkobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). *Ann Oncol* 2017; 28: 16-33.
 - 45) Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. *Ann Oncol* 2009; 21: 1243-1245.
 - 46) Masci G, Gandini C, Zuradelli M, Pedrazzoli P, Torrisi R, Lutman FR, Santoro A. Fulvestrant for advanced male breast cancer patients: a case series. *Ann Oncol* 2011; 22: 985.
 - 47) de la Haba Rodríguez JR, Porrás Quintela I, Pulido Cortijo G, Berciano Guerrero M, Aranda E. Fulvestrant in advanced male breast cancer. *Ann Oncol* 2009; 20: 1896-1897.
 - 48) Agrawal A, Ayantunde AA, Rampaul R, Robertson JFR. Male breast cancer: a review of clinical management. *Breast Cancer Res Treat* 2007; 103: 11-21.
 - 49) Helwick C. Is Male Breast Cancer Overlooked in Clinical Trials? *The ASCO Post* 2019.
 - 50) Jaga K, Dharmani C. The epidemiology of pesticide exposure and cancer: a review. *Rev Environ Health* 2005; 20: 15-38.
 - 51) Bounias M. Etiological factors and mechanism involved in relationships between pesticide exposure and cancer. *J Environ Biol* 2003; 24: 1-8.
 - 52) Weichenthal S, Moase C, Chan P. A review of pesticide exposure and cancer incidence in the agricultural health study cohort. *Environ Health Perspect* 2010; 118: 1117-1125.
 - 53) Natarajan R, Aljaber D, Au D, Thai C, Sanchez A, Nunez A, Resto C, Chavez T, Jankowska MM, Benmarhnia T, Yang JA, Jones V, Tomsic J, McCune JS, Sistrunk C, Doan S, Serrano M, Cardiff RD, Dietze EC, Seewaldt VL. Environmental exposures during puberty: window of breast cancer risk and epigenetic damage. *Int J Environ Res Public Health* 2020; 17: 493.
 - 54) Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Altman DG, Booth A, Chan A-, Chang S, Clifford T, Dickersin K, Egger M, Gøtzsche PC, Grimshaw JM, Groves T, Helfand M, Higgins J, Lasserson T, Lau J, Lohr K, McGowan J, Mulrow C, Norton M, Page M, Sampson M, Schünemann H, Simeira I, Summerskill W, Tetzlaff J, Trikalinos TA, Tovey D, Turner L, Whitlock E. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015; 4: 1.
 - 55) Davis DL, Blair A, Hoel DG. Agricultural exposures and cancer trends in developed countries. *Environ Health Perspect* 1993; 100: 39-44.
 - 56) Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. Blood levels of organochlorine residues and risk of breast cancer. *J Natl Cancer Inst* 1993; 85: 648-652.
 - 57) Krieger N, Wolff MS, Hiatt RA, Rivera M, Vogelmann J, Orentreich N. Breast cancer and serum organochlorines: a prospective study among white, black, and asian women. *J Natl Cancer Inst* 1994; 86: 589-599.
 - 58) Wiklund K, Dich J. Cancer risks among female farmers in sweden. *Cancer Causes Control* 1994; 5: 449-457.
 - 59) Kettles MA, Browning SR, Prince TS, Horstman SW. Triazine herbicide exposure and breast cancer incidence: An ecologic study of Kentucky counties. *Environ Health Perspect* 1997; 105: 1222-1227.
 - 60) Van 'T Veer P, Lobbezoo IE, Martín-Moreno JM, Guallar E, Gómez-Aracena J, Kardinaal AFM, Kohlmeier L, Martin BC, Strain JJ, Thamm M, Van Zoonen P, Baumann BA, Huttunen JK, Kok FJ. DDT (dicophane) and postmenopausal breast cancer in Europe: case-control study. *Br Med J* 1997; 315: 81-85.
 - 61) López-Carrillo L, Blair A, López-Cervantes M, Cebrián M, Rueda C, Reyes R, Mohar A, Bravo J. Dichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case-control study from Mexico. *Cancer Res* 1997; 57: 3728-3732.
 - 62) Hunter DJ, Hankinson SE, Laden F, Colditz GA, Manson JE, Willet WC, Speizer FE, Wolff MS. Plasma organochlorine levels and the risk of breast cancer. *New Engl J Med* 1997; 337: 1253-1258.
 - 63) Olaya-Contreras P, Rodríguez-Villamil J, Posso-Valencia HJ, Cortez JE. Organochlorine expo-

- sure and breast cancer risk in Colombian women. *Cad Saude Publica* 1998; 14: 125-132.
- 64) Petralia SA, Chow WH, McLaughlin J, Jin F, Gao YT, Dosemeci M. Occupational risk factors for breast cancer among women in Shanghai. *Am J Ind Med* 1998; 34: 477-483.
 - 65) Fleming LE, Bean JA, Rudolph M, Hamilton K. Cancer incidence in a cohort of licensed pesticide applicators in Florida. *J Occup Environ Med* 1999; 41: 279-288.
 - 66) Mendonça GAS, Eluf-Neto J, Andrada-Serpa MJ, Carmo PAO, Barreto HHC, Inomata ONK, Kussumi TA. Organochlorines and breast cancer: a case-control study in Brazil. *Int J Cancer* 1999; 83: 596-600.
 - 67) Fleming LE, Bean JA, Rudolph M, Hamilton K. Mortality in a cohort of licenced pesticide applicators in Florida. *Occup Environ Med* 1999; 56: 14-21.
 - 68) Ward EM, Schulte P, Grajewski B, Andersen A, Patterson DG, Turner W, Jellum E, Deddens JA, Friedland J, Roeleveld N, Waters M, Ann Butler M, Dipietro E, Needham LL. Serum organochlorine levels and breast cancer: a nested case-control study of Norwegian women. *Cancer Epidemiol Biomarkers Prev* 2000; 9: 1357-1367.
 - 69) Band PR, Le ND, Fang R, Deschamps M, Gallagher RP, Yang P. Identification of occupational cancer risks in British Columbia: a population-based case-control study of 995 incident breast cancer cases by menopausal status, controlling for confounding factors. *J Occup Environ Med* 2000; 42: 284-310.
 - 70) Aronson KJ, Miller AB, Wooleott CG, Sterns EE, McCready DR, Lickley LA, Fish EB, Hiraki GY, Holloway C, Ross T, Hanna WM, SenGupta SK, Weber JP. Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2000; 9: 55-63.
 - 71) Høyer AP, Jørgensen T, Grandjean P, Hartvig HB. Repeated measurements of organochlorine exposure and breast cancer risk (Denmark). *Cancer Causes Control* 2000; 11: 177-184.
 - 72) Stellman SD, Djordjevic MV, Britton JA, Muscat JE, Citron ML, Kemeny M, Busch E, Gong L. Breast cancer risk in relation to adipose concentrations of organochlorine pesticides and polychlorinated biphenyls in long island, new york. *Cancer Epidemiol Biomarkers Prev* 2000; 9: 1241-1249.
 - 73) Millikan R, Devoto E, Duell EJ, Tse CK, Savitz DA, Beach J, Edmiston S, Jackson S, Newman B. Dichlorodiphenyldichloroethene, polychlorinated biphenyls, and breast cancer among African-American and white women in North Carolina. *Cancer Epidemiol Biomarkers Prev* 2000; 9: 1233-1240.
 - 74) Demers A, Ayotte P, Brisson J, Dodin S, Robert J, Dewailly E. Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. *Cancer Epidemiol Biomarkers Prev* 2000; 9: 161-166.
 - 75) Duell EJ, Millikan RC, Savitz DA, Newman B, Smith JC, Schell MJ, Sandler DP. A population-based case-control study of farming and breast cancer in North Carolina. *Epidemiology* 2000; 11: 523-531.
 - 76) Dolapsakis G, Vlachonikolis IG, Varveris C, Tsatsakis AM. Mammographic findings and occupational exposure to pesticides currently in use on Crete. *Eur J Cancer* 2001; 37: 1531-1536.
 - 77) Janssens JP, Van Hecke E, Geys H, Bruckers L, Renard D, Molenberghs G. Pesticides and mortality from hormone-dependent cancers. *Eur J Cancer Prev* 2001; 10: 459-467.
 - 78) Thomas JK, Qin B, Howell DA, Richardson BE. Environmental hazards and rates of female breast cancer mortality in Texas. *Sociol Spectr* 2001; 21: 359-375.
 - 79) Mathur V, Bhatnagar P, Sharma RG, Acharya V, Sexana R. Breast cancer incidence and exposure to pesticides among women originating from Jaipur. *Environ Int* 2002; 28: 331-336.
 - 80) Safi JM. Association between chronic exposure to pesticides and recorded cases of human malignancy in Gaza governorates (1990-1999). *Sci Total Environ* 2002; 284: 75-84.
 - 81) Charlier C, Albert A, Herman P, Hamoir E, Gaspard U, Meurisse M, Plomteux G. Breast cancer and serum organochlorine residues. *Occup Environ Med* 2003; 60: 348-351.
 - 82) Brody JG, Aschengrau A, McKelvey W, Rudel RA, Swartz CH, Kennedy T. Breast cancer risk and historical exposure to pesticides from wide-area applications assessed with GIS. *Environ Health Perspect* 2004; 112: 889-897.
 - 83) O'Leary ES, Vena JE, Freudenheim JL, Brasure J. Pesticide exposure and risk of breast cancer: a nested case-control study of residentially stable women living on Long Island. *Environ Res* 2004; 94: 134-144.
 - 84) Muir K, Rattanamongkolgul S, Smallman-Raynor M, Thomas M, Downer S, Jenkinson C. Breast cancer incidence and its possible spatial association with pesticide application in two counties of England. *Public Health* 2004; 118: 513-520.
 - 85) Reynolds P, Hurley SE, Goldberg DE, Yerabati S, Gunier RB, Hertz A, Anton-Culver H, Bernstein L, Deapen D, Horn-Ross PL, Peel D, Pinder R, Ross RK, West D, Wright WE, Ziogas A; California Teachers Study. Residential proximity to agricultural pesticide use and incidence of breast cancer in the California Teachers Study cohort. *Environ Res* 2004; 96: 206-218.
 - 86) Mills PK, Yang R. Breast cancer risk in hispanic agricultural workers in California. *Int J Occup Environ Health* 2005; 11: 123-131.
 - 87) Raaschou-Nielsen O, Pavuk M, LeBlanc A, Dumas P, Weber JP, Olsen A, Tjønneland A, Overvad K, Olsen JH. Adipose organochlorine concentrations and risk of breast cancer among postmenopausal Danish women. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 67-74.

- 88) Engel LS, Hill DA, Hoppin JA, Lubin JH, Lynch CF, Pierce J, Samanic C, Sandler DP, Blair A, Alavanja MC. Pesticide use and breast cancer risk among farmers' wives in the agricultural health study. *Am J Epidemiol* 2005; 161: 121-135.
- 89) Zumbado M, Goethals M, Álvarez-León EE, Luzardo OP, Cabrera F, Serra-Majem L, Domínguez-Boada L. Inadvertent exposure to organochlorine pesticides DDT and derivatives in people from the Canary Islands (Spain). *Sci Total Environ* 2005; 339: 49-62.
- 90) Alavanja MCR, Sandler DP, Lynch CF, Knott C, Lubin JH, Tarone R, Thomas K, Dosemeci M, Barker J, Hoppin JA, Blair A. Cancer incidence in the agricultural health study. *Scand J Work Environ Health* 2005; 31: 39-45.
- 91) Waliszewski SM, Bermudez MT, Infanzon RM, Silva CS, Carvajal O, Trujillo P, Arroyo SG, Pietrini RV, Saldaña VA, Melo G, Esquivel S, Castro F, Ocampo H, Torres J, Hayward-Jones PM. Persistent organochlorine pesticide levels in breast adipose tissue in women with malignant and benign breast tumors. *Bull Environ Contam Toxicol* 2005; 75: 752-759.
- 92) Rubin CH, Lanier A, Kieszak S, Brock JW, Koller KR, Strosnider H, Needham L, Zahm S, Harpster A. Breast cancer among Alaska native women potentially exposed to environmental organochlorine chemicals. *Int J Circumpolar Health* 2006; 65: 18-27.
- 93) Khanjani N, English DR, Sim MR. An ecological study of organochlorine pesticides and breast cancer in rural Victoria, Australia. *Arch Environ Contam Toxicol* 2006; 50: 452-461.
- 94) Teitelbaum SL, Gammon MD, Britton JA, Neugut AI, Levin B, Stellman SD. Reported residential pesticide use and breast cancer risk on long island, new york. *Am J Epidemiol* 2007; 165: 643-651.
- 95) Cohn BA, Wolff MS, Cirillo PM, Scholtz RI. DDT and breast cancer in young women: new data on the significance of age at exposure. *Environ Health Perspect* 2007; 115: 1406-1414.
- 96) Itoh H, Iwasaki M, Hanaoka T, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Tsugane S. Serum organochlorines and breast cancer risk in Japanese women: a case-control study. *Cancer Causes Control* 2009; 20: 567-580.
- 97) Jacome GPO, Koifman RJ, Monteiro GTR, Koifman S. Environmental exposure and breast cancer among young women in Rio de Janeiro, Brazil. *J Toxicol Environ Health Part A Curr Iss* 2010; 73: 858-865.
- 98) Xu X, Dailey AB, Talbott EO, Ilacqua VA, Kearney G, Asal NR. Associations of serum concentrations of organochlorine pesticides with breast cancer and prostate cancer in U.S. adults. *Environ Health Perspect* 2010; 118: 60-66.
- 99) Zota AR, Aschengrau A, Rudel RA, Brody JG. Self-reported chemicals exposure, beliefs about disease causation, and risk of breast cancer in the Cape Cod Breast Cancer and Environment Study: a case-control study. *Environ Health Global Access Sci Sour* 2010; 9: 40.
- 100) Farooq U, Joshi M, Nookala V, Cheriya P, Fischman D, Graber NJ, Stellman SD, Muscat J. Self-reported exposure to pesticides in residential settings and risk of breast cancer: a case-control study. *Environ Health Global Access Sci Sour* 2010; 9: 30.
- 101) Waggoner JK, Kullman GJ, Henneberger PK, Umbach DM, Blair A, Alavanja MCR, Kamel F, Lynch CF, Knott C, London SJ, Hines CJ, Thomas KW, Sandler DP, Lubin JH, Beane Freeman LE, Hoppin JA. Mortality in the agricultural health study, 1993-2007. *Am J Epidemiol* 2011; 173: 71-83.
- 102) Ashley-Martin J, Vanleeuwen J, Cribb A, Andreou P, Guernsey JR. Breast cancer risk, fungicide exposure and CYP1A1*2a gene-environment interactions in a province-wide case control study in Prince Edward Island, Canada. *Int J Environ Res Public Health* 2012; 9: 1846-1858.
- 103) El-Zaemey S, Heyworth J, Fritschi L. Noticing pesticide spray drift from agricultural pesticide application areas and breast cancer: a case-control study. *Aust New Zealand J Public Health* 2013; 37: 547-555.
- 104) Holmes AK, Koller KR, Kieszak SM, Sjodin A, Calafat AM, Sacco FD, Varner DW, Lanier AP, Rubin CH. Case-control study of breast cancer and exposure to synthetic environmental chemicals among Alaska native women. *Int J Circumpolar Health* 2014; 73: 25760.
- 105) El-Zaemey S, Heyworth J, Glass DC, Peters S, Fritschi L. Household and occupational exposure to pesticides and risk of breast cancer. *Int J Environ Health Res* 2014; 24: 91-102.
- 106) Parrón T, Requena M, Hernández AF, Alarcón R. Environmental exposure to pesticides and cancer risk in multiple human organ systems. *Toxicol Lett* 2014; 230: 157-165.
- 107) Lerro CC, Koutros S, Andreotti G, Friesen MC, Alavanja MC, Blair A, Hoppin JA, Sandler DP, Lubin JH, Ma X, Zhang Y, Freeman LEB. Organophosphate insecticide use and cancer incidence among spouses of pesticide applicators in the agricultural health study. *Occup Environ Med* 2015; 72: 736-744.
- 108) Cohn BA, La Merrill M, Krigbaum NY, Yeh G, Park JS, Zimmermann L, Cirillo PM. DDT exposure in utero and breast cancer. *J Clin Endocrinol Metab* 2015; 100: 2865-2872.
- 109) Salerno C, Carcagni A, Sacco S, Palin LA, Vanhaecht K, Panella M, Guido D. An Italian population-based case-control study on the association between farming and cancer: are pesticides a plausible risk factor? *Archiv Environ Occup Health* 2016; 71: 147-156.
- 110) He TT, Zuo A-J, Wang J-G, Zhao P. Organochlorine pesticides accumulation and breast cancer: a hospital-based case-control study. *Tumor Biol* 2017; 39: 1010428317699114.
- 111) Wielsøe M, Kern P, Bonefeld-Jørgensen EC. Serum levels of environmental pollutants is a risk factor for breast cancer in Inuit: a case con-

- trol study. *Environ Health Global Access Sci Sour* 2017; 16: 56.
- 112) Engel LS, Werder E, Satagopan J, Blair A, Hopkin JA, Koutros S, Lerro CC, Sandler DP, Alavanja MC, Beane Freeman LE. Insecticide use and breast cancer risk among farmers' wives in the agricultural health study. *Environ Health Perspect* 2017; 125: 097002.
- 113) Eldakroory SA, Morsi DAE, Abdel-Rahman RH, Roshdy S, Gouida MS, Khashaba EO. Correlation between toxic organochlorine pesticides and breast cancer. *Hum Exp Toxicol* 2017; 36: 1326-1334.
- 114) Chang S, El-Zaemey S, Heyworth J, Tang MC. DDT exposure in early childhood and female breast cancer: evidence from an ecological study in Taiwan. *Environ Int* 2018: 1106-1112.
- 115) Silva AMC, Campos PHN, Mattos IE, Hajat S, Lacerda EM, Ferreira MJM. Environmental exposure to pesticides and breast cancer in a region of intensive agribusiness activity in Brazil: a case-control study. *Int J Environ Res Public Health* 2019; 16: 3951.
- 116) Huang W, He Y, Xiao J, Huang Y, Li A, He M, Wu K. Risk of breast cancer and adipose tissue concentrations of polychlorinated biphenyls and organochlorine pesticides: a hospital-based case-control study in Chinese women. *Environ Sci Pollut Res* 2019; 26: 32128-32136.
- 117) Cohn BA, Cirillo PM, Terry MB. DDT and breast cancer: prospective study of induction time and susceptibility windows. *J Natl Cancer Inst* 2019; 111: 803-810.
- 118) Cohn BA, Cirillo PM, La Merrill MA. Correlation of body mass index with serum DDTs predicts lower risk of breast cancer before the age of 50: prospective evidence in the child health and development studies. *J Expos Sci Environ Epidemiol* 2019; 29: 302-309.
- 119) Cocco P, Figgs L, Dosemeci M, Hayes R, Linet MS, Hsing AW. Case-control study of occupational exposures and male breast cancer. *Occup Environ Med* 1998; 55: 599-604.
- 120) Fleming LE, Bean JA, Rudolph M, Hamilton K. Cancer incidence in a cohort of licensed pesticide applicators in Florida. *J Occup Environ Med* 1999; 41: 279-288.
- 121) Fleming LE, Bean JA, Rudolph M, Hamilton K. Mortality in a cohort of licensed pesticide applicators in Florida. *Occup Environ Med* 1999; 56: 14-21.
- 122) Fleming LE, Gómez-Marín O, Zheng D, Ma F, Lee D. National health interview survey mortality among US farmers and pesticide applicators. *Am J Ind Med* 2003; 43: 227-233.
- 123) Macfarlane GJ, Biggs A, Maconochie N, Hotopf M, Doyle P, Lunt M. Incidence of cancer among UK Gulf war veterans: cohort study. *Br Med J* 2003; 327: 1373-1375.
- 124) Villeneuve S, Cyr D, Lynge E, Orsi L, Sabroe S, Merletti F, Gorini G, Morales-Suarez-Varela M, Ahrens W, Baumgardt-Elms C, Kaerlev L, Eriksson M, Hardell L, Fèveotte J, Guénel P. Occupation and occupational exposure to endocrine disrupting chemicals in male breast cancer: a case-control study in Europe. *Occup Environ Med* 2010; 67: 837-844.
- 125) Parrón T, Requena M, Hernández AF, Alarcón R. Environmental exposure to pesticides and cancer risk in multiple human organ systems. *Toxicol Lett* 2014; 230: 157-165.
- 126) Sabarwal A, Kumar K, Singh RP. Hazardous effects of chemical pesticides on human health—Cancer and other associated disorders. *Environ Toxicol Pharmacol* 2018; 63: 103-114.
- 127) Kaur K, Kaur R. Occupational pesticide exposure, impaired DNA repair, and diseases. *Indian J Occup Environ Med* 2018; 22: 74-81.
- 128) Ledda C, Loreto C, Zammit C, Marconi A, Fago L, Matera S, Costanzo V, Sanzà GF, Palmucci S, Ferrante M, Costa C, Fenga C, Biondi A, Pomara C, Rapisarda V. Non-infective occupational risk factors for hepatocellular carcinoma: a review (review). *Mol Med Rep* 2017; 15: 511-533.
- 129) Manasa K, Chitra V. Phytoconstituents in the management of pesticide induced Parkinson's disease: a review. *Biomed Pharmacol J* 2019; 12: 1417-1424.
- 130) Rapisarda V, Ledda C, Matera S, Fago L, Arrabito G, Falzone L, Marconi A, Libra M, Loreto C. Absence of t(14;18) chromosome translocation in agricultural workers after short-term exposure to pesticides. *Mol Med Rep* 2017; 15: 3379-3382.
- 131) Kim K, Kabir E, Jahan SA. Exposure to pesticides and the associated human health effects. *Sci Total Environ* 2017; 575: 525-535.
- 132) Czajka M, Matysiak-Kucharek M, Jodłowska-Jędrych B, Sawicki K, Fal B, Drop B, Krużewski M, Kapka-Skrzypczak L. Organophosphorus pesticides can influence the development of obesity and type 2 diabetes with concomitant metabolic changes. *Environ Res* 2019; 178: 108685.
- 133) Costa C, Rapisarda V, Catania S, Di Nola C, Ledda C, Fenga C. Cytokine patterns in greenhouse workers occupationally exposed to α -cypermethrin: an observational study. *Environ Toxicol Pharmacol* 2013; 36: 796-800.
- 134) Ledda C, Fiore M, Santarelli L, Bracci M, Mascali G, D'agati MG, Busà A, Ferrante M, Rapisarda V. Gestational hypertension and organophosphorus pesticide exposure: a cross-sectional study. *Biomed Res Int* 2015; 2015: 280891.
- 135) Pourhassan B, Meysamie A, Alizadeh S, Habibian A, Beigzadeh Z. Risk of obstructive pulmonary diseases and occupational exposure to pesticides: a systematic review and meta-analysis. *Public Health* 2019; 174: 31-41.
- 136) Mamane A, Baldi I, Tessier JF, Raheison C, Bouvier G. Occupational exposure to pesticides and respiratory health. *Eur Respir Rev* 2015; 24: 306-319.

- 137) Montana A, Rapisarda V, Esposito M, Amico F, Cocimano G, Nunno ND, Ledda C, Salerno M. A rare case of suicide by ingestion of phorate: a case report and a review of the literature. *Healthcare* 2021; 9: 131.
- 138) Mostafalou S, Abdollahi M. Pesticides: an update of human exposure and toxicity. *Arch Toxicol* 2017; 91: 549-599.
- 139) Ledda C, Cannizzaro E, Cinà D, Filetti V, Vitale E, Paravizzini G, Di Naso C, Iavicoli I, Rapisarda V. Oxidative stress and DNA damage in agricultural workers after exposure to pesticides. *J Occup Med Toxicol* 2021; 16: 1.
- 140) Vinceti M, Filippini T, Violi F, Rothman KJ, Costanzini S, Malagoli C, Wise LA, Odone A, Signorelli C, Iacuzio L, Arcolin E, Mandrioli J, Fini N, Patti F, Lo Fermo S, Pietrini V, Teggi S, Ghermandi G, Scillieri R, Ledda C, Mauceri C, Sciacca S, Fiore M, Ferrante M. Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. *Environ Health Global Access Sci Sour* 2017; 16: 91.
- 141) Longnecker MP, Rogan WJ, Lucier G. The human health effects of DDT (dichlorodiphenyl-trichloroethane) and PCBs (polychlorinated biphenyls) and an overview of organochlorines in public health. *Annu Rev Public Health* 1997; 18: 211-244.
- 142) EPA. Endocrine disruptor screening program: what are endocrine disruptors? *Endocrine Disruptor Screening Program: What are Endocrine Disruptors?* 2001.
- 143) Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Olea Serrano F. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. *Environ Health Perspect* 1995; 103: 113-122.
- 144) Korach KS, Sarver P, Chae K, McLachlan JA, McKinney JD. Estrogen receptor-binding activity of polychlorinated hydroxybiphenyls: conformationally restricted structural probes. *Mol Pharmacol* 1988; 33: 120-126.
- 145) Kelce WR, Stone CR, Laws SC, Gray LE, Kempainen JA, Wilson EM. Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. *Nature* 1995; 375: 581-585.
- 146) IARC. IARC monographs on the evaluation of carcinogenic risks to humans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 1994.
- 147) IARC. IARC monographs on the evaluation of carcinogenic risks to humans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 2018.
- 148) Chan M, Chang MC, González R, Lategan B, Del Barco E, Vera-Badillo F, Quesada P, Goldstein R, Cruz I, Ocana A, Cruz JJ, Amir E. Outcomes of estrogen receptor negative and progesterone receptor positive breast cancer. *PLoS One* 2015; 10.
- 149) Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. *J Cancer Res Clin Oncol* 2008; 134: 1347-1354.
- 150) Murphy CE, Carder PJ, Lansdown MRJ, Speirs V. Steroid hormone receptor expression in male breast cancer. *Eur J Surg Oncol* 2006; 32: 44-47.
- 151) Yue W, Yager JD, Wang JP, Jupe ER, Santen RJ. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. *Steroids* 2013; 78: 161-170.
- 152) Snedeker SM. Pesticides and breast cancer risk: a review of DDT, DDE and dieldrin. *Environ Health Perspect* 2001; 109: 35-47.
- 153) Gellert RJ, Heinrichs WL, Swerdloff RS. DDT homologues: estrogen-like effects on the vagina, uterus and pituitary of the rat. *Endocrinology* 1972; 91: 1095-1100.
- 154) López-Cervantes M, Torres-Sánchez L, Tobías A, López-Carrillo L. Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. *Environ Health Perspect* 2004; 112: 207-214.
- 155) Fenton SE, Reed C, Newbold RR. Perinatal environmental exposures affect mammary development, function, and cancer risk in adulthood. *Annu Rev Pharmacol Toxicol* 2012; 52: 455-479.
- 156) Rudel RA, Fenton SE, Ackerman JM, Euling SY, Makris SL. Environmental exposures and mammary gland development: state of the science, public health implications, and research recommendations. *Environ Health Perspect* 2011; 119: 1053-1061.
- 157) Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disruptors. *Environ Health Perspect* 2003; 111: 389-394.
- 158) Fenton SE, Birnbaum LS. Timing of environmental exposures as a critical element in breast cancer risk. *J Clin Endocrinol Metab* 2015; 100: 3245-3250.
- 159) Pike MC, Spicer DV, Dahmouch L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. *Epidemiol Rev* 1993; 15: 17-30.
- 160) Dehghan M, Baniasadi H, Fakhri Moghadam R, Salehi M. Cosmetic products don't increase the risk of breast cancer: a retrospective case-control study in southeast Iran. *WCRJ* 2020; 7: e1572.
- 161) Ebrahimzadeh E, Gholizadeh Pasha AR, Kamrani G, Yousefi T, Zahedian A, Tilaki KH, Qujeq D. Assessment of alpha-L-fucosidase and fucosyltransferase 4 enzymes in healthy and tumor tissues of patients with breast cancer. *WCRJ* 2020; 7: e1756.

- 162) Akbari Bazm M, Naseri L, Khazaei M. Methods of inducing breast cancer in animal models: a systematic review. *WCRJ* 2018; 5: e1182.
- 163) Bakhshi Aliabad H, Khanamani Falahati-Pour S, Ahmadi H, Mohamadi M, Reza Hajizadeh M, Bakhshi G, Mahmoodi M. Vanadium complex induced apoptosis in HepG2 cells by the up-regulation of p53, p21, and Caspase-8. *WCRJ* 2019; 6: e1293.
- 164) Del Buono A, D'orta A, Tarro G, Rossi P, Papa S, Iodice L, Abbadessa A, Montano L, Portale G, Berretta M, Di Francia R. "Terra dei fuochi, the starting point". The role of prevention and complementary medicine in the clinical practice. *WCRJ* 2018; 5: e1112.